Si no puede ver los articulos por favor descarguese el Acrobat Reader

Diurnal mood variation in major depressive disorder- F. Peeters - 2008        (LEER)

Journal of affective disorders - Murray        - 2008        (LEER)

Why do we need new and better antidepressants? - Stuart A.        Montgomery - 2008        (LEER)

Pathophysiology of depression and mechanisms of treatment -        2008       (LEER)

Agomelatine trial - Kennedy et al - Eur Neuropsy - 2006 (LEER)

Clinical Efficacy Agomelatine - Den Boer et al - Pharmacol - 2006
        (LEER)

Efficacy and tolerance profile of agomelatine and practical use in
        depressed patients - Rouillon - Psychopharmacol - 2006.pdf (LEER)

Determination of the Dose of Aglomenatine, in the treatment of
        major depression disorder, a placebo-controlled dose
        range study - Polwart - Inpharma - 2005 (LEER)

Absence of discontinuation symptoms with agomelatine and
        occurrence of discontinuation symptoms paroxetine - Montgomery
        et al - Psychopharmacol - 2004 (LEER)

Agomelatine in older men - Leproult et al - Clin Endocrinol - 2005
        (LEER)

Agomelatine enhancing - Millan et al - Pharmacol - 2003 (LEER)

Agomelatine penis erections - Chagraoui et al- Psychopharmacol -
        2003 (LEER)

Agomelatine versus fluoxetine - Hanoun et al - Neu - 2004 (LEER)

Antidepressant Agomelatine Serotonin - Bourin et al - J Psycho N -
        2004 (LEER)

Antidepressant Action Agomelatine - Barden et al - Prog Neuro Psy -
        2005 (LEER)

Use of S20098 and melatonin - Armstrong et al - Pharmacol Biochem
        and Beh - 1993 (LEER)

Agomelatine, a New Antidepressant, Induces Regional
        Changes in Hippocampal Neurogenesis (LEER)

Effect of Agomelatine - Norman et al - Int J Neuropsychopharmacol -
        2004 (LEER)

Effects of Agomelatine in the Chronic Mild Stress Model of
        Depression in the Rat - Papp et al - Neuropsy - 2003 (LEER)

Antidepressant action of agomelatine (S 20098) in a transgenic
        mouse model - Barden et al - Neuropsy - 2005 (LEER)

The Novel Melatonin Agonist Agomelatine (S20098) Is an
        Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of
        Which Enhances the Activity of Frontocortical Dopaminergic
        and Adrenergic PathwaysAgomelatine enhancing - Millan et al -
        Pharmacol - 2003 (LEER)

Preclinical evaluation of the reinforcing and discriminative stimulus
        effects of agomelatine (S-20098), a melatonin agonist - Willey et al -
        Psycopharmacol - 1998 (LEER)